Camacho KM, Menegatti S, Vogus DR, Pusuluri A, Fuchs Z, Jarvis M, Zakrewsky M, Evans MA, Chen R, Mitragotri S.  2016.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy. Journal of Controlled Release. 229:154-162.

Vaidya B, Kulkarni NS, Shukla SK, Parvathaneni V, Chauhan G, Damon JK, Sarode A, Garcia JV, Kunda N, Mitragotri S et al..  2020.  Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics. International Journal of Pharmaceutics. 577:118995.

Niu J, Lunn DJ, Pusuluri A, Yoo JI, O’Malley MA, Mitragotri S, H Soh T, Hawker CJ.  2017.  Engineering live cell surfaces with functional polymers via cytocompatible controlled radical polymerization. Nature Chemistry. 9

Vogus DR, Evans MA, Pusuluri A, Barajas A, Zhang M, Krishnan V, Nowak M, Menegatti S, Helgeson ME, Squires TM et al..  2017.  A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer. Journal of Controlled Release.

Camacho KM, Menegatti S, Mitragotri S.  2016.  Low-molecular-weight polymer–drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations. Nanomedicine. 11(9)

Camacho KM, Kumar S, Menegatti S, Vogus DR, Anselmo AC, Mitragotri S.  2015.  Synergistic antitumor activity of camptothecin–doxorubicin combinations and their conjugates with hyaluronic acid. Journal of Controlled Release. 210:198-207.

Zakrewsky M, Mitragotri S.  2016.  Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease. Journal of Controlled Release. 242:80-88.